Bioventus Inc.
BVS
$8.97
-$0.18-1.97%
NASDAQ
| 12/31/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 3,902.84% | 161.08% | 129.04% | 46.07% | 93.64% |
| Total Depreciation and Amortization | 22.18% | -7.10% | -7.95% | 0.68% | 0.35% |
| Total Amortization of Deferred Charges | -34.89% | -- | -- | -- | -16.67% |
| Total Other Non-Cash Items | -20.03% | 32.72% | -73.20% | 42.27% | 32.37% |
| Change in Net Operating Assets | 394.45% | 2,431.22% | -91.39% | -111.43% | -206.73% |
| Cash from Operations | 96.50% | 191.76% | 71.07% | -221.92% | 86.25% |
| Capital Expenditure | -1.05% | -639.06% | -787.01% | -183.85% | -55.56% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -100.00% | -- | -- | -- | 11,216.22% |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -102.41% | -639.06% | -1,677.92% | 17.40% | 4,178.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 40.43% | -- | 39.50% | -63.61% | -- |
| Issuance of Common Stock | -53.67% | -82.64% | 116.26% | -15.25% | 598.10% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -104.83% | -34,805.24% | -5,678.95% | -575.20% | 2,603.49% |
| Cash from Financing | 33.62% | -5,618.51% | -86.91% | 122.32% | -306,007.14% |
| Foreign Exchange rate Adjustments | 106.45% | -184.55% | 148.21% | 179.04% | -660.60% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 708.18% | -16.48% | 48.19% | -59.27% | -114.72% |